X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs GLENMARK PHARMA - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS GLENMARK PHARMA J.B.CHEMICALS/
GLENMARK PHARMA
 
P/E (TTM) x 18.2 19.7 92.2% View Chart
P/BV x 2.5 3.4 71.4% View Chart
Dividend Yield % 0.2 0.3 51.7%  

Financials

 J.B.CHEMICALS   GLENMARK PHARMA
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
GLENMARK PHARMA
Mar-18
J.B.CHEMICALS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs318930 34.2%   
Low Rs200517 38.6%   
Sales per share (Unadj.) Rs148.0322.6 45.9%  
Earnings per share (Unadj.) Rs19.128.5 67.0%  
Cash flow per share (Unadj.) Rs23.939.2 61.1%  
Dividends per share (Unadj.) Rs0.502.00 25.0%  
Dividend yield (eoy) %0.20.3 69.9%  
Book value per share (Unadj.) Rs128.9183.0 70.5%  
Shares outstanding (eoy) m84.82282.17 30.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.2 78.0%   
Avg P/E ratio x13.625.4 53.4%  
P/CF ratio (eoy) x10.818.5 58.5%  
Price / Book Value ratio x2.04.0 50.7%  
Dividend payout %2.67.0 37.3%   
Avg Mkt Cap Rs m21,951204,206 10.7%   
No. of employees `0002.713.7 19.9%   
Total wages/salary Rs m1,84118,718 9.8%   
Avg. sales/employee Rs Th4,590.96,636.8 69.2%   
Avg. wages/employee Rs Th673.41,364.7 49.3%   
Avg. net profit/employee Rs Th592.1586.1 101.0%   
INCOME DATA
Net Sales Rs m12,55191,031 13.8%  
Other income Rs m542914 59.3%   
Total revenues Rs m13,09391,945 14.2%   
Gross profit Rs m2,05516,154 12.7%  
Depreciation Rs m4123,019 13.7%   
Interest Rs m962,856 3.4%   
Profit before tax Rs m2,08811,193 18.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4693,155 14.9%   
Profit after tax Rs m1,6198,039 20.1%  
Gross profit margin %16.417.7 92.3%  
Effective tax rate %22.528.2 79.7%   
Net profit margin %12.98.8 146.0%  
BALANCE SHEET DATA
Current assets Rs m7,77869,887 11.1%   
Current liabilities Rs m4,35832,879 13.3%   
Net working cap to sales %27.240.7 67.0%  
Current ratio x1.82.1 84.0%  
Inventory Days Days5581 67.1%  
Debtors Days Days8093 85.6%  
Net fixed assets Rs m5,71328,892 19.8%   
Share capital Rs m170282 60.1%   
"Free" reserves Rs m10,54751,353 20.5%   
Net worth Rs m10,93751,635 21.2%   
Long term debt Rs m041,418 0.0%   
Total assets Rs m15,574125,954 12.4%  
Interest coverage x22.84.9 463.9%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.80.7 111.5%   
Return on assets %11.08.6 127.3%  
Return on equity %14.815.6 95.1%  
Return on capital %20.015.1 132.2%  
Exports to sales %48.70-   
Imports to sales %7.10-   
Exports (fob) Rs m6,115NA-   
Imports (cif) Rs m889NA-   
Fx inflow Rs m6,16936,317 17.0%   
Fx outflow Rs m1,2859,720 13.2%   
Net fx Rs m4,88426,598 18.4%   
CASH FLOW
From Operations Rs m1,39716,481 8.5%  
From Investments Rs m-320-10,133 3.2%  
From Financial Activity Rs m-1,196-4,685 25.5%  
Net Cashflow Rs m-1021,770 -5.8%  

Share Holding

Indian Promoters % 55.4 48.3 114.7%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 6.9 49.1%  
FIIs % 3.9 34.4 11.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 10.5 352.4%  
Shareholders   30,437 56,727 53.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   CIPLA  PFIZER  NATCO PHARMA  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare J.B.CHEMICALS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of India's Trade Deficit, Etihad Offer for Jet Airways, and Top Cues in Focus Today(Pre-Open)

On Wednesday, share markets in India traded on a volatile note throughout the day and ended on a flat note.The BSE Sensex closed higher by 3 points to end the day at 36321.

Related Views on News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)

Jan 4, 2019

Following a super investor can certainly help build a portfolio and create wealth in the long term.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

HDFC Bank Still Going Strong(Chart Of The Day)

Jan 4, 2019

The stock of HDFC Bank has continued to reward shareholders.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Jan 16, 2019 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 5-YR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS